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Abstract
Proteins associated with familial neurodegenerative disease often aggregate in patients’
neurons. Several such proteins, e.g. TDP-43, aggregate and are toxic when expressed in
yeast. Deletion of the ATXN2 ortholog, PBP1, reduces yeast TDP-43 toxicity, which led to
identification of ATXN2 as an amyotrophic lateral sclerosis (ALS) risk factor and therapeutic
target. Likewise, new yeast neurodegenerative disease models could facilitate identification
of other risk factors and targets. Mutations in SS18L1, encoding the calcium-responsive
transactivator (CREST) chromatin-remodeling protein, are associated with ALS. We show
that CREST is toxic in yeast and forms nuclear and occasionally cytoplasmic foci that stain
with Thioflavin-T, a dye indicative of amyloid-like protein. Like the yeast chromatin-remodel-
ing factor SWI1, CREST inhibits silencing of FLO genes. Toxicity of CREST is enhanced by
the [PIN+] prion and reduced by deletion of the HSP104 chaperone required for the propaga-
tion of many yeast prions. Likewise, deletion of PBP1 reduced CREST toxicity and aggrega-
tion. In accord with the yeast data, we show that the Drosophila ortholog of human ATXN2,
dAtx2, is a potent enhancer of CREST toxicity. Downregulation of dAtx2 in flies overexpres-
sing CREST in retinal ganglion cells was sufficient to largely rescue the severe degenerative
phenotype induced by human CREST. Overexpression caused considerable co-localization
of CREST and PBP1/ATXN2 in cytoplasmic foci in both yeast and mammalian cells. Thus,
co-aggregation of CREST and PBP1/ATXN2 may serve as one of the mechanisms of
PBP1/ATXN2-mediated toxicity. These results extend the spectrum of ALS associated pro-
teins whose toxicity is regulated by PBP1/ATXN2, suggesting that therapies targeting
ATXN2 may be effective for a wide range of neurodegenerative diseases.
Author summary
Mutations in the calcium-responsive transactivator (CREST) protein have been shown to
cause amyotrophic lateral sclerosis (ALS). Here we show that the human CREST protein
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expressed in yeast forms largely nuclear aggregates and is toxic. We also show that the
HSP104 chaperone required for propagation of yeast prions is likewise required for
CREST toxicity. Furthermore deletion of HSP104 affects CREST aggregation. ATXN2,
previously shown to modify ALS toxicity caused by mutations in the TDP-43 encoding
gene, also modifies toxicity of CREST expressed in either yeast or flies. In addition, dele-
tion of the yeast ATXN2 ortholog reduces CREST aggregation. These results extend the
spectrum of ALS associated proteins whose toxicity is regulated by ATXN2, suggesting
that therapies targeting ATXN2 may be effective for a wide range of neurodegenerative
diseases.
Introduction
Mutations in an increasing number of human genes have been found to cause familial neuro-
degenerative disease [1,2]. Proteins encoded by these genes are often soluble in healthy indi-
viduals, but form insoluble amyloid-like aggregates that seed further aggregation in the
neurons of patients with disease. For example, such conformational changes have been seen
for: Aβ, associated with Alzheimer’s disease; α-synuclein with Parkinson’s disease; TDP-43,
FUS and others with amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD);
and huntingtin with Huntington’s disease. Wild-type and mutant forms of these proteins are
respectively associated with aggregates in sporadic and familial forms of the diseases. Overex-
pression of either wild-type or mutant protein causes toxicity, although the mutant forms are
often toxic at lower concentrations than the wild-type [3].
Conformational change of several yeast proteins from a soluble state to insoluble self-seed-
ing aggregates, called prions, causes transmissible phenotypic changes [4–15]. Furthermore,
the presence of one prion aggregate enhances the de novo appearance of heterologous prions.
For example, the endogenous yeast prion [PIN+] (sometimes called [RNQ+]), which is an amy-
loid form of the RNQ1 protein, promotes the de novo aggregation of the SUP35 protein to
form the [PSI+] prion. This could occur by cross-seeding or by sequestration of proteins such
as chaperones by the amyloid [PIN+] prion [8,16–27].
Yeast has proved to be useful in the study of disease-specific proteins that form prion-like
aggregates [28–35]. When human proteins associated with aggregation in neurodegenerative
disease were expressed in yeast, they formed aggregates and caused toxicity. Curiously the tox-
icity of several of these proteins, e.g. TDP-43, FUS or huntingtin, is enhanced by the presence
of the [PIN+] prion [28,36,37]. These yeast models have allowed the identification of yeast
genes that either alter the disease protein’s aggregation or enhance or reduce its toxicity.
Remarkably, human homologs of these yeast modifier genes have confirmed, and identified
new human risk factors for Alzheimer’s (PICALM, XPO1, ADSSL1 and RABGEF1) [38–40],
Parkinson’s (PARK9) [38,41]) and ALS (ATXN2) [42–46]. Indeed, the discovery in yeast that
deletion of the ATXN2 (Ataxin-2) ortholog, PBP1, reduced TDP-43 toxicity, led to the recent
exciting finding that reduction in ATXN2 levels dramatically lowers neurotoxicity in ALS
mouse models [43]. Thus the establishment of new yeast neurodegenerative disease models
may lead to the identification of new risk factors for human disease as well as provide screen-
ing platforms for drug discovery.
Recently, mutations in SS18L1 have been shown to cause ALS [47,48]. SS18L1 encodes the
calcium-responsive transactivator (CREST) protein which is an essential component of the
nBAF neuron-specific chromatin remodeling complex that is related to the yeast SWI/SNF
chromatin remodeling complex [49–51]. Overexpression of CREST inhibits neurite outgrowth
A yeast model of calcium-responsive transactivator (CREST) proteinopathy
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in cultured neurons and causes retina degeneration in transgenic Drosophila [48,52]. Also,
CREST co-immunoprecipitates with FUS in neuron lysates [48,52]. In cultured cells, trans-
formed CREST forms predominantly nuclear dots with some cytoplasmic foci. Also, like other
ALS associated proteins, CREST is recruited to stress-induced ribonucleoprotein particle
(RNP) granules [52,53]. While many proteins must reversibly aggregate in physiological gran-
ules as part of their normal cellular function, this ability to aggregate could lead to the forma-
tion of pathological aggregates. Indeed, TDP-43 and FUS have prion-like domains and have
been found in cytoplasmic aggregates in the neurons of patients with ALS. While no such
aggregates have yet been reported for CREST, it has an unstructured prion-like domain pre-
dicted to form amyloid-like aggregates [48]. CREST in cell culture was slightly resistant to Tri-
ton-X100 but was solubilized by SDS; in addition it formed nuclear dots in a concentration-
dependent manner [52].
Here we establish a new ALS model in yeast. We show that this human chromatin remodel-
ing complex component and transcriptional activator is toxic and forms largely nuclear aggre-
gates that stain with Thioflavin T when expressed in yeast. We also show that CREST toxicity
is increased by the endogenous yeast [PIN+] prion and reduced by deletion of the HSP104
chaperone that is required for propagation of many yeast prions [4]. Deletion of the TDP-43
toxicity modifier, PBP1, likewise reduces CREST toxicity and this finding was also confirmed
in a CREST transgenic fly model. Both hsp104Δ and pbp1Δ alter CREST aggregation. Finally,
overexpression of PBP1 causes a large portion of CREST to leave the nucleus and co-localize
with PBP1 containing cytoplasmic dots in yeast. Likewise, in mammalian cells, cytoplasmic
aggregates of CREST sequester ATXN2. Overall, our results establish PBP1/ATXN2 as a potent
modifier of CREST toxicity in vivo.
Results
Expression of human CREST in yeast is toxic
Growth of yeast transformed with control GAL-GFP vectors was compared with yeast express-
ing fusions of human CREST cDNA and GFP from a GAL promoter on three types of vectors:
a Yeast CEN plasmid (YCp) containing a centromere and expressed as one or a few copies in
each cell (Fig 1A); a Yeast Episomal plasmid (YEp) containing elements of the endogenous
yeast 2μ episome and expressed in high copy in some cells but absent in other cells (Fig 1B); or
a Yeast Integrating plasmid (YIp) that was integrated into the genome (Fig 1C). Growth inhi-
bition is evident but slight when CREST-GFP was expressed from a CEN vector (Fig 1A) and
more inhibition is seen when episomal (Fig 1B) or integrating vectors (Fig 1C) were used.
Expression of the GAL controlled genes was turned on with a constitutively expressed fusion
of the human estrogen receptor hormone-binding domain, the yeast GAL4 DNA-binding
domain and the VP16 viral transcriptional activator, which was activated by the addition of β-
estradiol [54]. The high level of β-estradiol used here (2 μM) in glucose media results in more
expression from the GAL promoter than that obtained by traditional induction on 2% galac-
tose without β-estradiol [55]. Note the reduced induction of CREST caused by galactose rela-
tive to β-estradiol results in reduced toxicity (S1 Fig).
CREST forms largely nuclear and occasionally cytoplasmic amyloid-like
foci in yeast
Similar to mammalian cells [52], CREST-GFP expressed in yeast largely appeared as dots in
nuclei, but smaller cytoplasmic foci were also visible and were more frequent after longer
induction times (Fig 2A). Nuclear localization was confirmed by using DAPI stain or a
A yeast model of calcium-responsive transactivator (CREST) proteinopathy
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Fig 1. Expression of human CREST in yeast is toxic. Shown is the growth of cells carrying vectors encoding
GAL-CREST-GFP and a fusion protein that promotes induction of the GAL promoter in the presence of estradiol (pβ-
est) spotted on plasmid selective glucose plates without estradiol where CREST-GFP expression is Non-induced, or
with 2 μM β-estradiol where CREST-GFP expression is β-Estradiol Induced. Duplicates are independent transformants
or integrants. Cells grown on plasmid selective glucose plates were diluted to OD600 = 2 and then serially diluted
10-fold and spotted on the plates shown. The pβ-est plasmid expresses the fusion activator that is responsive to β-
estradiol, and YCpGAL-ccdB (pGALC) was used as its control. (A) CREST-GFP expressed from a CEN plasmid inhibits
growth. YCpGAL-CREST-GFP (pCRESTC) and control YCp-GAL-GFP (pGFPC) vectors were used. (B) CREST-GFP
expressed from a 2μ plasmid inhibits growth. YEpGAL-CREST-GFP (pCRESTE) and the control YEpGAL-GFP (pGFPE)
vectors were used. (C) Integrated CREST-GFP is toxic. Strain with integrated YIpGAL-CREST-GFP (pCRESTI) and
parent strain lacking the integrated plasmid but containing control YEpGAL-GFP (LEU2) was used. Strain 74D-694
[PIN+] was used for the CEN and integrated vector experiments (A and C) while strain BY4741 [PIN+] was used for the
2μ vector experiments (B).
https://doi.org/10.1371/journal.pgen.1008308.g001
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constitutively expressed nuclear HTB1-mCh marker (Fig 2B and S2 Fig) which co-localized
with CREST-GFP. CREST foci also stained with Thioflavin T that marks amyloid-like protein
(Fig 2C). For controls we show TDP-43 and FUS aggregates that, respectively do not and do,
stain with Thioflavin T [56]. In addition, the bulk of the CREST protein is found in the pellet of
lysates while the non-aggregated proteins, GFP and PGK, remain in the supernatant (Fig 2D).
When CREST was overexpressed in mammalian cells, it formed large dot-like nuclear
structures and was also present in cytoplasmic aggregates [52]. When CREST is expressed in
yeast for 5–6 h, most of the protein is found in nuclear dots with just occasional cytoplasmic
foci (see Figs 2 and 3 left). However, when cells with nuclear CREST are stressed by incubation
at high temperature there is a dramatic increase in the appearance of cytoplasmic foci (Fig 3
middle) that partially co-localize with Ded1-mCh stress granule and EDC3-mCh P-body
markers. Following a return to 30˚C, cytoplasmic CREST aggregates disappear along with
stress granules and P-bodies (Fig 3 right).
The presence of the [PIN+] prion or HSP104 enhances toxicity of CREST
Since the presence of the [PIN+] prion causes enhanced toxicity of the human genes hunting-
tin/polyQ, TDP-43 and FUS [28,36,37,57], we asked if [PIN+] would likewise increase toxicity
of CREST and found that it did (Fig 4A). However, CREST and [PIN+] aggregates did not co-
localize (Fig 4B). Also, CREST aggregated in both [PIN+] and [pin-] cells (Figs 2A and 4D).
Interestingly, CREST toxicity was reduced even further when the HSP104 chaperone required
for the propagation of many yeast prions [4,58] was deleted in [pin-] cells (Fig 4C left). Dele-
tion of HSP104 also caused the appearance of many nuclei with diffuse CREST-GFP with or
without dots instead of nuclear CREST-GFP dots on a black background, and reduced the
number of cells showing any cytoplasmic CREST aggregation (Fig 4D). CREST-GFP was
found largely in the pellet in lysates of both hsp104Δ and HSP104 yeast (Fig 4E). The higher
level of CREST-GFP in the hsp104Δ cultures (Fig 4C right) could reflect the reduced toxicity of
CREST.
Expression of human CREST activates yeast FLO genes and causes
flocculation
While working with GAL-CREST-GFP and GAL-GFP transformants, we noticed that expres-
sion of CREST-GFP caused cells in liquid culture to settle very rapidly compared to the GFP
controls. In a measured experiment, we found that overexpression of CREST caused floccula-
tion (cell clumping), while overexpression of TDP-43 or FUS did not (Fig 5A).
Since CREST increased yeast flocculence just as the non-prion form of the SWI1 chromatin
remodeling protein does [59], we hypothesized that CREST, like SWI1, remodels yeast chro-
matin structure causing a release of silencing of telomerically located and epigenetically con-
trolled [60] FLO genes, resulting in flocculation. To test this we examined the effect of CREST
on the telomerically located FLO1 and the epigenetically controlled FLO11 promoters, using
ura3Δ strains with either the FLO1 or FLO11 open reading frames (ORFs) replaced with the
URA3 ORF reporter [59]. In the absence of CREST these strains were auxotrophic for uracil
indicating that both the FLO1 and FLO11 promoters were off. However, upon CREST expres-
sion on galactose medium, both strains gained the ability to grow in the absence of uracil, indi-
cating that the FLO1 and FLO11 promoters were indeed both activated by CREST (Fig 5B).
Unlike [PIN+] aggregates, CREST dots do not seed SUP35 prion formation
Considerable evidence suggests that amyloid-like aggregates of one protein can facilitate the de
novo aggregation of certain heterologous proteins. Such a phenomenon could be an important
A yeast model of calcium-responsive transactivator (CREST) proteinopathy
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risk factor for disease. While there are no yeast proteins that are homologous to the human
CREST, the yeast protein with the most similarity to CREST, using a BLAST search, is RNQ1,
the [PIN+] protein. This is likely due to the extensive QN-rich regions in both proteins. Thus,
we asked if aggregates of CREST, like [PIN+] and other QN-rich aggregates, could facilitate the
de novo aggregation of SUP35 to form the [PSI+] prion. In [PIN+] but not [pin-] cells, transient
overexpression of SUP35NM-GFP causes the appearance of large fluorescent SUP35NM-GFP
rings and converts [psi-] cells into [PSI+] [8,17,55,61]. Here we detect conversion into [PSI+],
which causes readthrough of nonsense codons, by the appearance of adenine prototrophy
despite the presence of the nonsense mutation ade1-14. We found that unlike [PIN+], or over-
expression of a variety of QN-rich yeast proteins [8], overexpression of CREST did not cause
the appearance of fluorescent SUP35NM-GFP rings or adenine prototrophy. This was true
even when PBP1 was also overexpressed (S3 Fig), which, as described below in the last research
section, drives CREST-DsRED aggregates into the cytoplasm.
PBP1/dAtx2 enhances toxicity of CREST in yeast and flies
Overexpression of yeast’s PBP1, a homolog of human ATXN2, enhances, while PBP1 deletion
reduces, the toxicity of TDP-43 expressed in yeast [42]. This led to the discovery that ATXN2
intermediate-length polyglutamine expansions, which are associated with increased ATXN2
protein levels, are a risk factor for ALS [42]. Work in a variety of model organisms including
mice, now suggests that ATXN2 is a modifier of some neurodegenerative diseases [43].
We thus tested the effect of PBP1 level on the toxicity of CREST in yeast. Overexpression of
PBP1 itself was toxic in our system (Fig 6A) so the effect on CREST toxicity could not be deter-
mined. However, we clearly show that deletion of PBP1 reduces toxicity in either a [PIN+] or
[pin-] background (Fig 6B) and this is associated with an increase in CREST-GFP solubility
(Fig 2D). Indeed, lysates of pbp1Δ cells expressing CREST-GFP had more GFP reactive protein
in the supernatant vs. pellet fractions while the reverse was true for PBP1 lysates. Furthermore
the CREST-GFP in pbp1Δ supernatant showed a lot of degradation compared with
CREST-GFP in the pellet or in either supernatant or pellet fractions of the isogenic PBP1 strain
(Fig 2D). This is likely because soluble CREST-GFP is more susceptible to degradation than
aggregated CREST-GFP found in the pellet. We also saw a significant reduction in the number
of cells with cytoplasmic CREST aggregates in the presence of pbp1Δ (Fig 6C). Taken together
the data imply that a smaller fraction of total CREST-GFP is aggregated in either nuclei or
cytoplasm in the absence of PBP1.
Fig 2. Human CREST expressed in yeast forms largely nuclear dots with occasional cytoplasmic foci. (A)
CREST-GFP expressed in yeast. BY4741 [PIN+] transformed with YEpGAL-CREST-GFP and pβ-est was induced for 6 or
24 h by growth in plasmid selective glucose media with 2 μM β-estradiol and examined under a fluorescent microscope.
Below is shown the % of cells containing CREST-GFP that contained one or more cytoplasmic dots. All of these cells
also had nuclear dots. (B) Co-localization of wild-type CREST-GFP aggregates and DAPI nuclear stain. Cells in (a)
induced for 6 h were stained with DAPI. (C) CREST aggregates stained with the Thioflavin T (ThT). Top row: BY4741
transformed YEpGAL-CREST-YFP (CREST-YFP) and pβ-est was induced for 6 h with 2 μM β-estradiol. Next three
rows strain L3491 transformed with YEpGAL-CREST-YFP (CREST-YFP), YCpGAL-TDP-43-YFP (TDP-43-YFP) as
negative control, or YCpGAL-FUS-YFP (FUS-YFP) as a positive control, were grown in plasmid selective SRGAL
medium overnight. ThT fluorescence was detected with a CFP filter. CFP was recolored green and YFP recolored red to
facilitate visualization of merged pictures. Cell boundaries are drawn. (D) CREST-GFP is found mostly in pellets in WT
but mostly in supernatant of pbp1Δ strains. Three independent transformants of (WT) and (pbp1Δ) with pβ-est and
either YEpGAL-CREST-GFP (CREST) or control YEpGAL-GFP (GFP) were grown on plasmid selective glucose
medium, induced with 2 μM β-estradiol for 6 h and harvested. Total lysates were separated into Supernatant and Pellet
by centrifugation. Samples were run on SDS-PAGE. Three gels were immunoblotted with anti-GFP, stripped and
reprobed with anti-PGK for loading control. All gels showed a ratio of more GFP reactive material in pellets of WT vs.
supernatant and the reverse for pbp1Δ. Since ratios are used loading differences are not relevant.
https://doi.org/10.1371/journal.pgen.1008308.g002
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In order to validate the observed effect of the ATXN2 ortholog PBP1 in an independent in
vivo model, we used transgenic Drosophila which possesses an ortholog of the human ATXN2
gene, dAtx2. Overexpression of untagged wild-type CREST using GAL4-UAS system in trans-
genic lines results in severe retinal degeneration [52]. For our studies we used dAtx2 deletion
fly line (dAtx2 06490) [62]. Homozygous deletion of dAtx2 was reported to cause disorganized
and decreased photoreceptor neurons, but there was no effect in the heterozygous state [62].
Fig 3. Heat stress causes relocalization of some CREST aggregates from the nucleus to the cytoplasm. CREST
partially co-localizes with the DED1 stress granule and EDC3 P-body markers during heat-stress and returns to the
nucleus following heat-stress. YCpDED1-mCh and YCpEDC3-mCh transformants of [PIN+] 74D-694 with integrated
GAL-CREST-EGFP were grown in plasmid selective SRaf (2%) to OD600 = 0.3 when CREST-EGFP was induced by
addition of 2% galactose for 5 h. Cells were then stressed for 20 min at 46˚C. CREST-EGFP, DED-mCh and
EDC3-mCh were examined before (30˚C), during (46˚C) and 3 h following (30˚C) heat stress.
https://doi.org/10.1371/journal.pgen.1008308.g003
A yeast model of calcium-responsive transactivator (CREST) proteinopathy
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Fig 4. Toxicity of CREST is reduced by the absence of the [PIN+] prion, and is further reduced by the absence of HSP104. (A)The
[PIN+] prion enhances toxicity of CREST in yeast. Shown is the growth (as in Fig 1) of [PIN+] and [pin-] BY4741 cells carrying
A yeast model of calcium-responsive transactivator (CREST) proteinopathy
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YEpGAL-CREST-GFP (pCRESTE) or control YEpGAL-GFP (pGFPE) and the pβ-est plasmid or empty control YCpGAL-ccdB (pGALC) on
plasmid selective glucose media in the presence (β-Estradiol Induced) and absence (Non-induced) of β-estradiol. (B) [PIN+] and CREST
aggregates do not co-localize. [PIN+] BY4741 carrying pβ-est, YEpGAL-CREST-DsRed (CREST-DsRed) and YCpRNQ-GFP (RNQ1-GFP)
were grown for 2 d on plates containing 50 μM CuSO4 and 2 μM β-estradiol to respectively induce RNQ1-GFP and CREST-DsRed and
were then examined with a fluorescence microscope. (C) The absence of HSP104 reduces CREST toxicity. Left: Independent transformants
of HSP104 (Wild-type) or hsp104Δ versions of [pin-] BY4741 carrying pβ-est and YEpGAL-CREST-GFP (pCRESTE) or control
YEpGAL-GFP (pGFPE) vectors were serially diluted and spotted on plasmid selective glucose without (Non-induced) or with 2 μM β-
estradiol (β-estradiol Induced). Right: Same transformants were grown in liquid plasmid selective dextrose media and induced with β-
estradiol for 6 h. Blots probed with GFP antibody to detect CREST were stripped and reprobed with phosoglycerate kinase (PGK) antibody
to detect the PGK loading control. (D) CREST aggregation is reduced in the absence of HSP104. HSP104 (Wild-type) or hsp104Δ versions of
[pin-] BY4741 carrying pβ-est and YEpGAL-CREST-GFP grown on plates for 3 d in plasmid selective dextrose medium containing 2 μM β-
estradiol were examined with a fluorescence microscope. Among cells expressing CREST-GFP we quantified the percent of cells with:
nuclear fluorescent dots, nuclear fluorescent dots on a diffuse nuclear background, nuclei with just diffuse fluorescence and one or more
cytoplasmic fluorescent dots. (E) CREST sediments largely in the pellet in lysates of HSP104-WT or hsp104Δ cells. Transformants grown in
liquid plasmid selective dextrose media and induced with β-estradiol for 6 h were harvested. Lysates were separated into Supernatant and
Pellet factions by centrifugation and samples were run on SDS-PAGE. Two gels immunoblotted with anti-GFP, stripped and reprobed with
anti-PGK for loading control gave identical results.
https://doi.org/10.1371/journal.pgen.1008308.g004
Fig 5. Expression of CREST enhances yeast flocculation. (A) CREST but not TDP-43 or FUS overexpression enhances
flocculation. Shown are transformants of BY4741 [PIN+] with: YCpGAL-CREST-GFP (CREST), YCpGAL-TDP-43-YFP
(TDP-43), YCpGAL-FUS-YFP (FUS) or control YCp-GAL-GFP with the average and standard error of OD600 of 10X
diluted supernatants after cells of 3 independent transformants were allowed to settle for 15 min. (B) Expression of
CREST activates the FLO1 and FLO11 promoters. Strains deleted for URA3 and containing either the FLO1(L3580) or
FLO11(L3582) open reading frames (ORFs) replaced with the URA3 ORF reporter, respectively prFLO1:URA and
prFLO11:URA were transformed with YEpGAL-CREST-GFP (pCRESTE) or control YEpGAL-GFP (pGFPE). Three
independent transformants of each were spotted on plasmid selective glucose media (Non-induced), with (+Ura) or
without (-Ura) uracil or plasmid selective -Ura galactose media (Gal Induced).
https://doi.org/10.1371/journal.pgen.1008308.g005
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Fig 6. Effects of PBP1 on CREST. (A) Overexpression of PBP1 is toxic. Serial dilutions of [PIN+] carrying pβ-est and YEpGAL-CREST-GFP
(pCRESTE) or control YEpGAL-GFP (pGFPE) and YCpGAL-PBP1-GFP (pPBP1C) or control YCpGAL (pGALC), were spotted on plasmid
selective dextrose (Non-inducing) or β-estradiol containing (β-estradiol Induced) plates and photographed after 3 d at 30 ˚C. (B) Deletion
of PBP1 reduces CREST toxicity. Independent transformants of [PIN+] or [pin-] without (WT) and with the deletion (pbp1Δ) carrying
YEpGAL-CREST-GFP (pCRESTE) or empty GFP control YEpGAL-GFP (pGFPE) and all carrying pβ-est expressing the fusion activator
responsive to β-estradiol, were spotted and grown on plasmid selective media with (β-est Induced), and without (Non-induced), β-
estradiol. (C) Deletion of PBP1 alters CREST aggregation. Transformants were grown for 2 d on medium with β-estradiol and were then
examined. Counts were performed on 3 independent transformants each to determine the fraction of cells with CREST-GFP that had
nuclei with dots on a black background, nuclei with dots on a diffuse background and one or more cytoplasmic dots.
https://doi.org/10.1371/journal.pgen.1008308.g006
A yeast model of calcium-responsive transactivator (CREST) proteinopathy
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We crossed CREST overexpressing (transgenic, tg) flies with heterozygous dAtx2 flies
(dAtx206490-/+) and analyzed the double tg progeny. Histological analysis confirmed normal
retinal morphology in dAtx206490-/+ flies, whereas complete disruption of the regularly ordered
arrays of photoreceptor neurons was observed in the retina in CRESTwt tg flies, consistent
with the previous report [52]. Strikingly, this severe retinal degenerative phenotype in
CRESTwt tg flies was largely rescued by downregulation of dAtx2 (CRESTwt tg; dAtx206490- /+
line) (Fig 7A and 7B). This rescue was not caused by reducing the expression of CREST (Fig
7C). Thus, human CREST toxicity in flies is largely mediated by endogenous dAtx2.
PBP1/ATXN2 and CREST co-localize in cytoplasmic foci in yeast and
human cells
Finally, we asked whether potentiated toxicity of CREST in the presence of PBP1 might be
linked to the aggregation-prone nature of the two proteins. We found a dramatic increase in
cytoplasmic CREST dots when PBP1 was overexpressed in yeast (Fig 8A). This was not due to
an increase in CREST protein level (Fig 8B). We also found the CREST-DsRed dots co-local-
ized with PBP1-GFP in cytoplasmic foci (Fig 8C). However these foci do not appear to be RNP
granules because they generally lack DED1 and EDC3 (S4 Fig).
We next examined the localization of human ATXN2 in CREST-overexpressing human
cells. CREST-GFP forms nuclear aggregates in cells expressing high levels of the protein, and
in the ~10% of cells with the highest levels of CREST-GFP, cytoplasmic aggregates also develop
[52]. We found that cytoplasmic CREST-GFP aggregates sequester endogenous ATXN2 in
human neuroblastoma cells under these conditions (Fig 8D middle), whereas in non-trans-
fected (NT) cells and in cells lacking these aggregates, ATXN2 remains diffusely distributed
(Fig 8D, top and bottom). Thus, CREST and PBP1/ATXN2 co-localize in the cytoplasm,
which may serve as one of the mechanisms of PBP1/ATXN2-mediated toxicity.
Discussion
Our data show that human CREST expressed in yeast shares properties with other ALS-associ-
ated proteins and yeast prions: CREST, FUS and yeast prions form amyloid-like foci; CREST,
TDP-43 and FUS toxicity and yeast prion appearance are enhanced by the yeast prion [PIN+];
TDP-43 and CREST toxicity is reduced by deletion of PBP1; CREST, TDP-43 and FUS are
associated with cytoplasmic RNP granules. Like maintenance of yeast prions, but unlike effects
on FUS or TDP-43 [31,32], CREST toxicity and aggregation is dependent on the presence of
HSP104 chaperone.
In mammals, endogenous CREST is a member of a chromatin remodeling complex and
thereby activates transcription. When expressed in yeast, we found that CREST releases telo-
meric silencing and causes flocculation. Thus we propose that even in yeast the heterologous
CREST protein remodels chromatin causing transcriptional activation of telomerically located
genes including those that cause flocculation (e.g. FLO1, FLO5, FLO9 and FLO10) as well as
the epigenetically controlled gene FLO11. Likewise, a yeast chromatin remodeling complex
protein, SWI1, is required for the expression of telomerically located and epigenetically con-
trolled FLO genes [63]. Interestingly, SWI1 can form infectious prion aggregates [12] reminis-
cent of the amyloid CREST aggregates seen here.
We first described [PIN+], the prion form of the RNQ1 protein, because its presence
allowed the efficient conversion of the SUP35 protein to its prion form, [PSI+] [8,17,64]. It was
later shown that [PIN+] is also required for the efficient aggregation and toxicity of polyQ in
yeast [28]. The mechanisms causing these effects are still unknown. Some data support the
hypothesis that the [PIN+] aggregates of RNQ1 cross-seed aggregation of heterologous
A yeast model of calcium-responsive transactivator (CREST) proteinopathy
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Fig 7. Heterozygous deletion of the Drosophila ortholog of ATXN2, dAtx2, reduced retinal degeneration induced by
human CREST. (A,B) Downregulation of dAtx2 rescues retinal degenerative phenotype in CREST transgenic flies. H&E staining
of retinal sections of 5-day-old flies reveals severe disruption of regularly ordered arrays of photoreceptor neurons in human
CRESTwt tg flies, but this phenotype is rescued upon heterozygous deletion of dAtx2 (CRESTwt tg x dAtx206490/+ line).
Representative images (A) and quantification (B) for each transgenic fly line are shown. N = 10 for LacZ, LacZ; LacZ
A yeast model of calcium-responsive transactivator (CREST) proteinopathy
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proteins such as SUP35 and polyQ. Likewise some, but not all, evidence suggests that the
[PIN+] aggregates bind proteins such as chaperones that would otherwise inhibit aggregation
of the heterologous SUP35 or polyQ protein, thereby enhancing their aggregation [18–25,27]
We recently showed that toxicity of TDP-43 and FUS is slightly enhanced by the presence
of [PIN+] [37,57]. Both of these proteins contain Q/N-rich regions and co-aggregate with
polyQ disease protein alleles of huntingtin [65,66]. Surprisingly, we did not detect a clear effect
of [PIN+] on TDP-43 or FUS aggregation. Likewise, CREST is a Q-rich protein. We show here
that the toxicity of CREST is also slightly enhanced by [PIN+], again with no clear effect on
aggregation. Apparently the toxicity of the aggregates can be altered without a noticeable
change in their appearance. On the other hand, deletion of either HSP104 or PBP1, which both
cause dramatic rescues of CREST toxicity, were each accompanied by reduced frequency of
CREST cytoplasmic foci, more diffuse CREST in nuclei and, for pbp1Δ, reduced CREST
sedimentation.
Surprisingly, despite the fact that we clearly detect more diffuse CREST in the presence of
hsp104Δ, there was no increase in CREST degradation or in the level of CREST in supernatant
fractions as was seen for pbp1Δ. Also, immunoblots of pbp1Δ lysates reproducibly show that
CREST-GFP in the supernatant is degraded much more in the pbp1Δ vs. WT PBP1 strain.
CREST-GFP in the pellet fractions was stable in either PBP1 or pbp1Δ strains. This suggests
that pbp1Δ causes more CREST to remain unaggregated and subject to degradation. Indeed
there was more CREST-GFP plus GFP breakdown product in the supernatant vs. pellet in the
pbp1Δ while the reverse was true for the PBP1 strain. While pbp1Δ also rescues toxicity of
TDP-43, effects on TDP-43 aggregation have not been reported [42].
Since the HSP104 chaperone is required to shear the [PSI+] prion aggregates thereby creat-
ing ends where growth occurs, inhibition of HSP104 initially causes [PSI+] prion polymers to
enlarge and, for newly made SUP35-GFP, to not efficiently join the aggregates remaining dif-
fuse instead [67]. Possibly something similar is happening to CREST-GFP in the absence of
HSP104. It is also possible that HSP104 is directly involved in CREST aggregate formation.
A recent finding that deletion of PBP1 causes a reduction in the level of RNQ1 protein [68]
could have explained the reduced CREST, TDP-43 and FUS toxicity seen in pbp1Δ cells if the
lowered RNQ1 level reduced the potency of [PIN+]. However, we show here that this is not the
case because pbp1Δ reduces CREST toxicity even in the absence of [PIN+] (Fig 6E). It remains
possible that toxicity is reduced by pbp1Δ by reducing RNQ1 levels regardless of [PIN+] status.
We have shown that the presence of certain QN-rich aggregates can substitute for [PIN+]
and allow the efficient induction of [PSI+] by overexpression of SUP35 [8]. This fact, plus the
observation that RNQ1, the [PIN+] prion protein, although not a homolog, is the yeast protein
most similar to CREST, prompted us to ask if overexpression of CREST could substitute for
[PIN+]. However, CREST did not provide any [PIN+] activity even when PBP1 was overex-
pressed driving CREST into the cytoplasm.
Prion aggregates enhance de novo formation of heterologous prion, presumably by a cross-
seeding mechanism. Curiously, however, if heterologous prion is already present, prion aggre-
gates instead promote loss of the heterologous prion [20]. One mechanism for this has been
shown to be prion aggregate binding to, and therefore titrating, chaperones needed to propa-
gate the heterologous prion [24]. Likewise, CREST has been shown to suppress polyQ-medi-
ated huntingtin aggregation and toxicity [69].
dAtx206490/+ and CRESTwt tg lines and N = 8 for the CRESTwt tg dAtx206490/+ line (3 sections per fly). (��) p<0.01, (�)
p<0.05, one-way ANOVA, post-hoc Tukey’s test. Scale bar is 100 μm. (C) Heterozygous deletion of dAtx2 does not alter retinal
expression of CREST. Protein isolated from heads of 5-day-old flies were analyzed as described in materials and methods. α-
tubulin was used as control.
https://doi.org/10.1371/journal.pgen.1008308.g007
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Fig 8. CREST and PBP1/ATXN2 co-localize in cytoplasmic aggregates in yeast and human cells. (A)
Overexpression of PBP1 enhances CREST cytoplasmic aggregation. Nine co-transformants of [PIN+] or [pin-] BY4741
with pβ-est and YEpGAL-CREST-GFP and either YCpGAL-PBP1 ("PBP1) or YCpGAL (Control) were patched and
grown on plasmid selective glucose media, velveteen replica-plated and grown on selective plates with β-estradiol for 3
A yeast model of calcium-responsive transactivator (CREST) proteinopathy
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Many of the ALS associated proteins, e.g. TDP-43, FUS and TAF15 are soluble nuclear
RNA/DNA binding proteins that regulate mRNA splicing and/or stability and contain prion-
like unstructured domains and nuclear/cytoplasmic trafficking signals. In neurons of patients
with ALS/FTD these proteins have been found in cytoplasmic aggregates instead of their nor-
mal nuclear location. This suggests that impaired nucleocytoplasmic transport may be a gen-
eral mechanism for neurotoxicity [3,70–75]. Indeed, impairing nuclear import of TDP-43
enhances neurotoxicity [76].
While TDP-43 and FUS quickly form cytoplasmic aggregates in yeast with little or no
nuclear localization [31,32,37,57,77–79], we found here that CREST appeared in nuclear
aggregates with only occasional cytoplasmic foci. While the ALS-associated proteins TDP-43,
FUS and SOD1 form aggregates in patients, model systems and in vitro, these aggregates are
sometimes but not always classical amyloids. In yeast, aggregates of FUS, but not TDP-43,
stain with Thioflavin T that is indicative of amyloid-like protein [56]. Although both nuclear
and cytoplasmic CREST foci appear to stain with Thioflavin T, it is nonetheless tempting to
speculate, by analogy with FUS and TDP-43, that the CREST cytoplasmic foci are more toxic
than nuclear CREST. Indeed reduction of CREST-GFP toxicity caused by deletion of either
PBP1 or HSP104 also reduced the frequency of cells with cytoplasmic CREST-GFP aggregates.
We found that heat stress induced CREST to leave the nucleus and partially co-localize with
RNP granules. This is consistent with previous findings in mammalian cells that CREST
becomes mislocalized to the cytoplasm under stressful conditions (oxidative stress) and
becomes recruited to cytoplasmic stress granules [52]. Furthermore, as seen for classic stress
granule proteins, CREST returned to the nucleus in yeast following the heat stress. Many pro-
teins associated with neurodegenerative disease contain intrinsically disordered regions that
are required for their appearance in RNP granules. Evidence has been accumulating that RNP
granules are incubators for the formation of pathogenic protein aggregates associated with
neurodegenerative disease. It has been proposed that localization of proteins such as TDP-43,
FUS and C9ORF72-encoded dipeptide repeat GR50 in high concentration in stress granules
likely in a gel form, promotes their conversion into pathogenic amyloid-like aggregates [80–
84].
In support of this model, RNP-granule formation has been shown to be strongly associated
with neurodegeneration. This was accomplished with the aid of ATXN2, a nucleic-acid-bind-
ing protein that is required for RNP-granule formation. Three ALS associated proteins, TDP-
43, FUS and C9ORF72-encoded GR dipeptide, have been shown to co-localize with ATXN2 in
RNP granules [42,80] in yeast, human or Drosophila S2 cells. Also, either reducing the level of
ATXN2 or deleting one of its intrinsically disordered regions both reduced RNP-granule for-
mation and reduced neurodegeneration caused by TDP-43, C9ORF72 dipeptides or FUS
[80,85–87]. These results help explain why expansions of the polyQ regions in ATXN2 that
d and examined with a fluorescent microscope. All transformants with "PBP1 had a dramatic increase in cytoplasmic
foci compared with controls. Shown are representative cells of each type. (B) PBP1 expression does not increase CREST
levels. Western blot of [PIN+] transformed with pβ-est and YEpGAL-CREST-GFP and either YCpGAL-PBP1 ("PBP1)
or control vector YCpGAL, grown in liquid plasmid selective dextrose media and induced with β-estradiol for 6 hrs.
Blots probed with GFP antibody to detect CREST were stripped and reprobed with phosoglycerate kinase (PGK)
antibody to detect the PGK loading control. (C). CREST co-localizes with PBP1 in cytoplasmic foci induced by PBP1
overexpression. YEpGAL-CREST-DsRED (CREST) and YCpGAL-PBP1-GFP (PBP1) were co-transformed into
BY4741 [PIN+]. Transformants patched on plasmid selective glucose medium were velveteen replica-plated, grown on
selective SGal for 3 d and examined with a fluorescent microscope. (D) CREST-GFP overexpressed in neuroblastoma
cells sequesters ATXN2 into spontaneously formed cytoplasmic aggregates. Cells with cytoplasmic CREST aggregates
(cyt.agg.+) sequester ATXN2. In cells with only nuclear CREST aggregates (cyt.agg.-) or in non-transfected (NT) cells,
ATXN2 remains diffuse. Cells were transfected to express CREST-GFP and were analyzed 24 h post-transfection. Scale
bar, 10 μm.
https://doi.org/10.1371/journal.pgen.1008308.g008
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increase the stability, and thus likely the level of ATXN2, are associated with neurodegenera-
tive disease (susceptibility to ALS and type 2 spinocerebellar ataxia).
Here, we report similar effects of PBP1/ATXN2 on CREST: deletion of PBP1 reduces toxic-
ity of CREST in yeast and fly models of CREST proteinopathy; ATXN2 is recruited into cyto-
plasmic CREST aggregates in mammalian cells and overexpression of PBP1 causes CREST to
co-localize with PBP1 in cytoplasmic foci in yeast. Overexpression of PBP1 has previously
been shown to induce the formation of cytoplasmic PBP1 foci [88] that recruit TORC1 thereby
down regulating TORC1 function [89]. PBP1 foci may similarly attract CREST which may
promote CREST’s conversion to a more toxic form. In sum, we showed that CREST is yet
another protein, in addition to TDP-43, that is highly sensitive to ATXN2 dosage indicating
that ATXN2 likely has a more general role as a modifier of neurotoxicity.
Our results extend the spectrum of ALS-associated proteins affected by ATXN2 to include
CREST. This supports the hypothesis that therapies that target ATXN2 may be effective for a
wide range of neurodegenerative diseases.
Methods
Yeast strains and plasmids
Yeast strains and plasmids used are listed in Tables 1 and 2. Unless otherwise stated, yeast
strain BY4741 (MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0) was used. Yeast transformation was by
the lithium acetate method [90]. L3491 bearing an integrated copy of ADH1-HTB1-mCh was
used to check CREST nuclear localization [37]. FLO1 (L3580) and FLO11 (L3582) promoter
reporter strains were respectively made from DY755 and DY758. DY755 and DY758 are Ura+
because FLO8, which is disrupted in these strains, is required for regulation that inhibits the
FLO1 and FLO11 promoters [59,91]. We obtained pop-outs of the HIS3 disruptions of FLO8
by selecting for Ura- revertants on FOA plates [92] and checking these for those that had
become His-. Several such pop-outs were obtained and tested and they all behaved identically.
Unless otherwise stated, all overexpression plasmids were driven by the GAL1 promoter. Gate-
way technology [93] was used to make CREST entry clone pDONR-CREST with BP reactions
between pDONR221 (Invitrogen, Cat# 12536017) and a CREST fragment amplified from
Table 1. Yeast strains used.
Strains Description Reference
74D-694 MATa ade1-14 ura3-52 leu2-3,112 trp1-289 his3-200 [55]
L2910 74D-694 [psi-] [pin-] [55]
L1749 74D-694 [psi-] [PIN+] [55]
L3536 L1749 GAL-CREST-EGFP:: LEU2 This study
L3491 74D-694 [psi-] [PIN+] HTB1-mCh::LEU2 [37]
L3496 [pin-] version of L3491 [37]
BY4741 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 [98]
L3270 BY4741 [psi-] [PIN+] [55]
L3269 BY4741 [psi-] [pin-] [55]
L3539 BY4741 [psi-] [PIN+] pbp1Δ::KanMX4 [99]
L3570 BY4741 [psi-] [pin-] pbp1Δ::KanMX4 This study
L3540 BY4741 [psi-] [pin-] hsp104Δ::KanMX4 [99]
DY755 BY4741 flo8::FLO8::HIS3 flo1Δ::FLO1promoter-URA3 [59]
L3580 BY4741 flo1Δ::FLO1promoter-URA3 This study
DY758 BY4741 flo8::FLO8::HIS3 flo11Δ::FLO11promoter-URA3 [59]
L3582 BY4741 flo11Δ::FLO11promoter-URA3 This study
https://doi.org/10.1371/journal.pgen.1008308.t001
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pC1-CREST with PCR. The CREST fragment in pDONR-CREST was further transferred to
YEpGAL-GFP, YCp-GAL-GFP, YEpGAL-DsRED and YIpGAL-GFP to respectively build YEp-
GAL-CREST-GFP, YCpGAL-CREST-GFP, YEpGAL-CREST-DsRED and YIpGAL-CREST-GFP
with LR reactions. To increase expression of GAL1 controlled CREST, pβ-est, containing
human estrogen receptor hormone-binding domain fused to the GAL4 DNA binding domain
and the VP16 viral transcriptional activator (hER) was used.
Cultivation procedures
Standard media and growth conditions were used [94,95]. All liquid-culture experiments were
carried out with mid-log-phase cells. Complex (YPD) yeast media contained 2% dextrose. Syn-
thetic medium lacked a specific component, e.g. leucine, and contained 2% dextrose, e.g.,
SD-Leu (-Leu medium) or 2% galactose without (SGal-Leu) or with 2% raffinose (SRGal-Leu).
Cells co-transformed with pβ-est, containing hER, were grown in β-estradiol (2 μM) in glucose
media to turn on expression of GAL1 controlled CREST [54],[55]. FOA medium containing
12 mg/l 5-fluoro-orotic acid and 12 mg/l uracil was used to select for Ura- cells [92]. To pre-
vent the accumulation of suppressor mutants that reverse CREST toxicity, pGAL1-CREST
transformants were maintained on plasmid selective SD medium where CREST was not
expressed. Patches were then replica-plated onto synthetic glycerol (2%) to identify petites that
were dropped from further study. To analyze growth, non-petite transformants from SD plates
were normalized in water to an OD600 of 2 and serially diluted 10X. Finally about 5 μl of
diluted cell suspensions were spotted on plasmid selective SD, SGal or SD + β-estradiol using
an MC48 (Dan-kar Corp, MA) spotter.
Table 2. Plasmids used.
Short name and SWL Laboratory Plasmid # Original Plasmid Name/Description Reference
pβ-est, p798 pHCA/GAL4(1–93).ER.VP16 (HIS3) [54]
YCpSUP35NM-GFP, p1181 pRS413-CUP1-SUP35NM-GFP (HIS3) [61]
YCpRNQ-GFP, p1185 pCUP1-RNQ-GFP (CEN, TRP1) [19]
YCp-GAL-GFP, p1764 pAG416-GAL1-ccdB-EGFP (CEN, URA3) Addgene plasmid #14195
YCpGAL-TDP-43-YFP, p2042 pRS416-GAL-TDP-43-YFP (CEN, URA3) Addgene plasmid #27447
YCpGAL-FUS-YFP, p2043 pAG416-GAL1-FUS-YFP (CEN, URA3) This study
YCpGAL-ccdB, p2186 pAG413-GAL-ccdB (CEN, HIS3) Addgene plasmid #14153
YCpGAL-PBP1, p2228 pBY011-GAL1-PBP1 (CEN, URA3) [42]
YCpGAL, p2229 pBY011-GAL1 (CEN, URA3) [93]
pC1-CREST, p2342 pEGFP-C1-CREST [52]
pDONR-CREST p2370 pDONR-CREST without stop codon This study
YCpGAL-CREST-GFP, p2375 pAG416-GAL1-CREST-EGFP (CEN, URA3) This study
YEpGAL-GFP, p2380 pAG425-GAL-ccdB-GFP (2μ, LEU2) Addgene plasmid #14201
YEpGAL-CREST-GFP, p2381 pAG425-GAL1-CREST-EGFP (2μ, LEU2) This study
YEpGAL-DsRED, p2387 pAG425-GAL-ccdB-DsRED (2μ, LEU2) Addgene plasmid #14369
YEpGAL-CREST-DsRED, p2389 pAG425-GAL1-CREST-DsRED (2μ, LEU2) This study
YIpGAL-CREST-GFP, p2391 pAG305-GAL1-CREST-EGFP (YIp, LEU2) This study
YIpGAL-GFP, p2425 YCpAG305-GAL-ccdB-EGFP (YIp, LEU2) Addgene plasmid #14185
YCpGAL-PBP1-EGFP, p2444 pAG416-GAL-PBP1-EGFP (CEN, URA3) This study
YCpEDC3-mCh, p2452 pRP1574, pEDC3-mCh (CEN, URA3) [100]
YCpDED1-mCh, p2453 pRP2132, pDED1-mCh (CEN, URA3) [101]
YCpGAL-PBP1-TRP, p2514 pAG414-GAL-PBP1 (CEN,TRP1) This study
YEpGAL-CREST-YFP, p2471 pAG423-GAL1-CREST-YFP (2μ, HIS3) This study
https://doi.org/10.1371/journal.pgen.1008308.t002
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Western blot analysis
CREST was detected in pre-cleared lysates separated by SDS-PAGE and blotted as described
previously [96]. For analysis of proteins in total lysate vs. supernatant and pellet, the pellet
from 90 μg of total lysate centrifuged at 50K rpm for 6 min was resuspended in water to the
initial volume of total lysate centrifuged. The same sample volumes of total lysate, supernatant
and pellet were then separated by SDS-PAGE. Blots were developed with GFP mouse antibody
from Roche Applied Science (Indianapolis, IN) and PGK antibody from life technologies
(Frederick, MD).
Visualization of aggregates, nuclei and co-localization studies
Fluorescently labeled protein aggregates, were visualized in cells with a Nikon Eclipse E600
fluorescent microscope (100X oil immersion) equipped with FITC, YFP and mCh (respec-
tively, chroma 49011, 49003 and 49008) filter cubes. To visualize nuclei, cells with the inte-
grated HTB1-mCh nuclear marker were used [37] or nuclei were stained with 1 μg/ml 40,60-
diamidino-2- phenylindole (DAPI) in 1XPBS for 10 min following fixing and permeabilizing
cells for 1 h in 60% ethanol in PBS.
Flocculation assay
Flocculation was assayed by resuspending a sample of each 2 d culture grown in plasmid selective
SRGal in 50 mM EDTA in water. Since flocculation requires the presence of Ca2+ ions [97],
EDTA removed clumping allowing cells’ OD600 to be accurately measured. Then another sample
of cells that was not treated with EDTA was appropriately normalized to OD600 = 10. Cells were
photographed after they were allowed to settle for 15 min. The level of precipitation of cells and
the reduction in the OD of the supernatants (diluted 10X) is a measure of the flocculence.
Thioflavin T Staining
Yeast cells were stained with Thioflavin T according to a protocol adapted from [31] with the
addition of two extra washes in PMST [0.1 M KPO4 (pH 7.5), 1 mM MgCl2, 1 M Sorbitol,
0.1% Tween 20].
Generation and characterization of transgenic flies
Generation of the human CREST line used in this study has been described earlier [52]. gmr-
GAL4, UAS-lacZ and dAtx2 06490 lines were obtained from the Bloomington Drosophila stock
center. Fly stocks were raised on standard Drosophila medium at 20˚C. Crosses between the
Drosophila strains were carried out at 25˚C using standard procedures. For histochemical
analyses, heads of 5-day-old adult transgenic flies were dissected, collected, briefly washed in
phosphate buffered saline (PBS), and fixed with 4% paraformaldehyde containing 0.1% Triton
X-100 at room temperature for 2 h. After a brief wash in PBS, tissues were dehydrated by
graded ethanol, cleared in butanol and embedded in paraffin. Four-micrometer thick coronal
sections were stained with hematoxylin and eosin (H&E). Between 8 and 10 flies were analyzed
per genotype, and 3 sections were analyzed for each fly. For Western blot analysis, heads of
5-day-old flies were lysed in Laemmli sample buffer containing 2% SDS. Anti-CREST (Pro-
teintech, 12439-1-AP) and anti-α-tubulin (Sigma, DM1A) antibodies were used.
Human cell culture and immunofluorescent analysis
WT CREST in pEGFP-C1 vector (Clontech) was used for CREST-GFP overexpression [52].
SH-SY5Y neuroblastoma cells were cultured in 1:1 mixture of Dulbecco’s Modified Eagle’s
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Medium (DMEM) and F12 medium supplemented with 10% FBS, 50 U/ml penicillin-strepto-
mycin, and 500 μM L-glutamine (all Invitrogen). Cells were fixed with 4% cold paraformalde-
hyde for 15 min at RT and permeabilized with methanol. Cells were incubated with a primary
anti-ATXN2 antibody (rabbit polyclonal, 21776-1-AP, Proteintech) diluted in PBS-T contain-
ing 5% goat serum at room temperature for 2 h. Fluorochrome-conjugated secondary antibody
(AlexaFluor, Life Technologies) diluted 1:1,000 in PBS-T were applied at RT for 1.5 h. Nuclei
were stained with DAPI and mounted on glass slides using Immu-Mount (Thermo Scientific).
Fluorescent images were taken using a BX57 fluorescent microscope equipped with ORCA-
Flash 4.0 camera (Hamamatsu) and cellSens Dimension software (Olympus). Figures were
prepared using Photoshop CS3 software.
Supporting information
S1 Fig. GAL-CREST-GFP is more toxic when expressed with β-estradiol than galactose.
Cells transformed with pβ-est and YEpGAL-CREST-GFP (pCRESTE) or the control YEp-
GAL-GFP (pGFPE) were serially diluted and spotted on plasmid selective glucose (Non-
induced), galactose (Galactose induced) or glucose with 2μM β-estradiol medium.
(TIF)
S2 Fig. Co-localization of wild-type CREST-GFP aggregates and nuclear marker
HTB1-mCh in [PIN+] and [pin-] strains. The strains L3491 and L3496 with integrated plas-
mid encoding ADH1-HTB1-mCh transformed with YCpGAL-CREST-GFP were grown on
plasmid selective SRGal medium for 24 h and examined.
(TIF)
S3 Fig. CREST does not facilitate induction of [PSI+]. Isogenic [PIN+] and [pin-] 74D-694
strains transformed with plasmids YEpGAL-CREST-DsRED ("CREST-DsRED) and CUP1-
SUP35NM-GFP ("SUP35NM-GFP) and YCpGAL-PBP1-EGFP ("PBP1) were patched on plas-
mid selective SGal plates with 50 μM CuSO4 and grown overnight. Cells were then examined
under a fluorescent microscope with a GFP filter (upper) or mCherry filter (lower) and rep-
lica-plated onto medium lacking adenine (-Ade) where only [PSI+] cells can grow. Plates were
photographed after incubation. Patches of three independent transformants of [PIN+] and
[pin-] are shown (middle).
(TIF)
S4 Fig. CREST-GFP foci formed by overexpression of PBP1 generally do not contain the
RNP granule markers DED1 or ECD3. L1749 transformed with YEpGAL-CREST-GFP, YCp-
GAL-PBP1-TRP and either YCpDED1-mCh or YCpEDC3-mCh were grown on plasmid selec-
tive galactose media and examined. DED1 failed to form any dots while EDC3 dots were very
rare in these stress-free cultures.
(TIF)
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